Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity.
J Korean Med Sci · 2010
Last updated 2026-05-28In lab tests, a GLP-1 drug called Exendin-4 (Ex-4) reduced cell death in insulin-producing cells by about 42% when those cells were exposed to oxidative stress. Ex-4 also lowered activity of proteins linked to cell death (GSK3β, JNK, caspase-9, and caspase-3) and helped restore insulin production in these cells.
AI summary of the abstract below.
| Journal | J Korean Med Sci, 2010 |
|---|---|
| Citations | 43 |
| Relative citation ratio | 1.24 |
| NIH percentile | 58 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Oxidative stress induced by chronic hyperglycemia in type 2 diabetes plays a crucial role in progressive loss of β-cell mass through β-cell apoptosis. Glucagon like peptide-1 (GLP-1) has effects on preservation of β-cell mass and its insulin secretory function. GLP-1 possibly increases islet cell mass through stimulated proliferation from β-cell and differentiation to β-cell from progenitor cells. Also, it probably has an antiapoptotic effect on β-cell, but detailed mechanisms are not proven. Therefore, we examined the protective mechanism of GLP-1 in β-cell after induction of oxidative stress. The cell apoptosis decreased to ~50% when cells were treated with 100 µM H(2)O(2) for up to 2 hr. After pretreatment of Ex-4, GLP-1 receptor agonist, flow cytometric analysis shows 41.7% reduction of β-cell apoptosis. This data suggested that pretreatment of Ex-4 protect from oxidative stress-induced apoptosis. Also, Ex-4 treatment decreased GSK3β activation, JNK phosphorylation and caspase-9, -3 activation and recovered the expression of insulin2 mRNA in β-cell lines and secretion of insulin in human islet. These results suggest that Ex-4 may protect β-cell apoptosis by blocking the JNK and GSK3β mediated apoptotic pathway.
Verbatim abstract via PubMed 21060752 ↗